TETRAULT LYNN A. sold $59K of NEO
TETRAULT LYNN A. sold 5,307 shares of NEOGENOMICS INC (NEO) at $11.10 on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of fundamental updates make it a low-conviction catalyst.
What to watch
The filing does not state reasons for sale, and the net impact depends on whether there are additional insider transactions around the same period, which are not provided here.
Background
The article is an SEC Form 4 insider transaction disclosure for Neogenomics (NEO).
Ticker impact
Neogenomics director Lynn A. Tetrault sold 5,307 shares at $11.10 on 2026-06-15 under a pre-arranged 10b5-1 plan, per Form 4.
Low likelihood of a sustained price move from this filing alone; any reaction would be sentiment-driven and likely short-lived.
The disclosure is an open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, and the article provides no accompanying company-specific operational or financial catalyst.
Market effects
No sector-level implications; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Insider sales under 10b5-1 plans can reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact.
Key entities
- issuerNEOGENOMICS INC
Company whose director insider sale is disclosed on Form 4.
- insiderTETRAULT LYNN A.
Director who sold 5,307 shares at $11.10 under a 10b5-1 plan.
